

# Yves Collette

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/171961/publications.pdf>

Version: 2024-02-01

93  
papers

4,830  
citations

87888

38  
h-index

98798

67  
g-index

103  
all docs

103  
docs citations

103  
times ranked

7738  
citing authors

#	ARTICLE	IF	CITATIONS
1	CRCM5484: A BET-BDII Selective Compound with Differential Anti-leukemic Drug Modulation. Journal of Medicinal Chemistry, 2022, 65, 5660-5674.	6.4	2
2	RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia, 2022, 36, 1237-1252.	7.2	12
3	A gain-of-function RAC2 mutation is associated with bone-marrow hypoplasia and an autosomal dominant form of severe combined immunodeficiency. Haematologica, 2021, 106, 404-411.	3.5	18
4	The NANOTUMOR consortium "Towards the Tumor Cell Atlas. Biology of the Cell, 2021, 113, 272-280.	2.0	1
5	Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia. Journal of Experimental Medicine, 2021, 218, .	8.5	56
6	Synergy and allostery in ligand binding by HIV-1 Nef. Biochemical Journal, 2021, 478, 1525-1545.	3.7	4
7	Development of ICT01, a first-in-class, anti-BTN3A antibody for activating V $\beta$ 9V $\alpha$ 2 T cell-mediated antitumor immune response. Science Translational Medicine, 2021, 13, eabj0835.	12.4	49
8	H3.3K27M Mutation Controls Cell Growth and Resistance to Therapies in Pediatric Glioma Cell Lines. Cancers, 2021, 13, 5551.	3.7	10
9	An Autosomal Dominant Form of Ras-Related C3 Botulinum Toxin Substrate 2 (RAC2) Is Associated with Haematopoiesis Failure. Blood, 2021, 138, 4306-4306.	1.4	0
10	<i>In silico</i> molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor. Molecular Oncology, 2020, 14, 3083-3099.	4.6	17
11	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. Blood Advances, 2020, 4, 5203-5214.	5.2	18
12	A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. Blood Cancer Journal, 2020, 10, 64.	6.2	18
13	A genome-wide <i>scRNA</i> screen reveals essential therapeutic targets of breast cancer stem cells. EMBO Molecular Medicine, 2019, 11, e9930.	6.9	27
14	An Autosomal Dominant SCID Form Due to a Gain of Function Mutation in the RAC2 Gene. Blood, 2019, 134, 3742-3742.	1.4	0
15	Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Frontiers in Immunology, 2018, 9, 977.	4.8	25
16	Integrated Strategy for Lead Optimization Based on Fragment Growing: The Diversity-Oriented-Target-Focused-Synthesis Approach. Journal of Medicinal Chemistry, 2018, 61, 5719-5732.	6.4	51
17	Cegal Protocol : Evaluation of the Feasibility of a Chemogenomic Approach to Identify Personalized Therapy for Relapse or Refractory AML Patients. Blood, 2018, 132, 1401-1401.	1.4	0
18	Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism. Cancer Discovery, 2017, 7, 716-735.	9.4	582

#	ARTICLE	IF	CITATIONS
19	Nectin-4: a new prognostic biomarker for efficient therapeutic targeting of primary and metastatic triple-negative breast cancer. <i>Annals of Oncology</i> , 2017, 28, 769-776.	1.2	77
20	JAM-C Identifies Src Family Kinase-Activated Leukemia-Initiating Cells and Predicts Poor Prognosis in Acute Myeloid Leukemia. <i>Cancer Research</i> , 2017, 77, 6627-6640.	0.9	23
21	Abstract 4140: Identification of a selective MKLP2/KIF20A inhibitor with high-in-vivo antitumor activity. , 2017, , .		0
22	Protein-Protein Interaction Inhibition (2P2I)-Oriented Chemical Library Accelerates Hit Discovery. <i>ACS Chemical Biology</i> , 2016, 11, 2140-2148.	3.4	33
23	Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. <i>Blood</i> , 2016, 128, 253-264.	1.4	320
24	BTN3A molecules considerably improve V $\beta$ 9V $\gamma$ 2T cells-based immunotherapy in acute myeloid leukemia. <i>Oncotarget</i> , 2016, 5, e1146843.	4.6	46
25	Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer. <i>Nature Communications</i> , 2016, 7, 10318.	12.8	85
26	Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-terminal Domain (BET) Proteins. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1634-1641.	6.4	79
27	Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2015, 5, e292-e292.	6.2	21
28	A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6559-6573.	6.4	33
29	A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2015, 5, e297-e297.	6.2	68
30	Context-Selective Death of Acute Myeloid Leukemia Cells Triggered by the Novel Hybrid Retinoid-HDAC Inhibitor MC2392. <i>Cancer Research</i> , 2014, 74, 2328-2339.	0.9	33
31	566 GNS396 and analogues are potent new small molecules to target and kill chemotherapy-resistant subpopulation cells in acute myeloid leukemia. <i>European Journal of Cancer</i> , 2014, 50, 183.	2.8	0
32	Therapeutic Targeting of c-Myc in T-Cell Acute Lymphoblastic Leukemia (T-ALL). <i>Oncotarget</i> , 2014, 5, 3168-3172.	1.8	58
33	Stereoselective synthesis of original spirolactams displaying promising folded structures. <i>Organic and Biomolecular Chemistry</i> , 2013, 11, 4719.	2.8	15
34	The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression. <i>Clinical Cancer Research</i> , 2013, 19, 6520-6531.	7.0	122
35	CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6711-6721.	0.9	91
36	Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. <i>Leukemia</i> , 2012, 26, 662-674.	7.2	72

#	ARTICLE	IF	CITATIONS
37	Tumor Selective Cytotoxic Action of a Thiomorpholin Hydroxamate Inhibitor (TMI-1) in Breast Cancer. PLoS ONE, 2012, 7, e43409.	2.5	4
38	Human V $\beta$ 9V $\alpha$ 2 T Cells Specifically Recognize and Kill Acute Myeloid Leukemic Blasts. Journal of Immunology, 2012, 188, 4701-4708.	0.8	112
39	Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy. Journal of Clinical Immunology, 2012, 32, 632-646.	3.8	42
40	Structural recognition mechanisms between human Src homology domain 3 (SH3) and ALG-2-interacting protein X (Alix). FEBS Letters, 2012, 586, 1759-1764.	2.8	9
41	Design of N-substituted Amino Caproic Hydroxamic Acid Histone Deacetylase Inhibitors Reveal an Essential Role for Cap Atomic Composition. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 801-806.	1.7	0
42	A specific protein disorder catalyzer of HIV-1 Nef. Bioorganic and Medicinal Chemistry, 2011, 19, 7401-7406.	3.0	4
43	Defective Triggering of NK Cells Results in Primary CLL Cells Resistance to Cytotoxicity,. Blood, 2011, 118, 3876-3876.	1.4	0
44	Identification and biophysical assessment of the molecular recognition mechanisms between the human haemopoietic cell kinase Src homology domain 3 and ALG-2-interacting protein X. Biochemical Journal, 2010, 431, 93-102.	3.7	9
45	Modified Cap Group Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivatives Reveal Improved Selective Antileukemic Activity. Journal of Medicinal Chemistry, 2010, 53, 3038-3047.	6.4	44
46	Stereoselective ring contraction of 2,5-diketopiperazines: An innovative approach to the synthesis of promising bioactive 5-membered scaffolds. Bioorganic Chemistry, 2010, 38, 210-217.	4.1	23
47	A simplified, 96-well-adapted, ATP luminescence-based motility assay. BioTechniques, 2009, 47, 871-875.	1.8	4
48	Anti-Leukemia Activity of MS-275 Histone Deacetylase Inhibitor Implicates 4-1BBL/4-1BB Immunomodulatory Functions. PLoS ONE, 2009, 4, e7085.	2.5	18
49	Alternative Splicing Modulates Autoinhibition and SH3 Accessibility in the Src Kinase Fyn. Molecular and Cellular Biology, 2009, 29, 6438-6448.	2.3	31
50	Synergistic Activation of HIV-1 Expression by Deacetylase Inhibitors and Prostratin: Implications for Treatment of Latent Infection. PLoS ONE, 2009, 4, e6093.	2.5	222
51	Protein-protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 19256-19261.	7.1	116
52	Amine-Guanidine Switch: A Promising Approach to Improve DNA Binding and Antiproliferative Activities. Journal of Medicinal Chemistry, 2007, 50, 6465-6475.	6.4	57
53	Anti-Acute Myeloid Leukemia Activity of Chaetocin, a Novel Epigenetic Drug Inhibitor Inducing Oxidative Stress.. Blood, 2007, 110, 889-889.	1.4	1
54	Signaling-dependent immobilization of acylated proteins in the inner monolayer of the plasma membrane. Journal of Cell Biology, 2006, 174, 255-265.	5.2	28

#	ARTICLE	IF	CITATIONS
55	Active Transcription of the Human FASL/CD95L/TNFSF6 Promoter Region in T Lymphocytes Involves Chromatin Remodeling. <i>Journal of Biological Chemistry</i> , 2006, 281, 14719-14728.	3.4	16
56	Evidences for ubiquitination and intracellular trafficking of LAT, the linker of activated T cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2005, 1746, 108-115.	4.1	26
57	A Role for the Neuronal Protein Collapsin Response Mediator Protein 2 in T Lymphocyte Polarization and Migration. <i>Journal of Immunology</i> , 2005, 175, 7650-7660.	0.8	64
58	Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity. <i>Nucleic Acids Research</i> , 2005, 33, 4285-4310.	14.5	30
59	Dynamic recruitment of the adaptor protein LAT: LAT exists in two distinct intracellular pools and controls its own recruitment. <i>Journal of Cell Science</i> , 2004, 117, 1009-1016.	2.0	114
60	Altered splicing in hematological malignancies reveals a tissue-specific translational block of the Src-family tyrosine kinase fyn brain isoform expression. <i>Leukemia</i> , 2004, 18, 1737-1739.	7.2	5
61	Functional interaction of RasGAP-binding proteins Dok-1 and Dok-2 with the Tec protein tyrosine kinase. <i>Oncogene</i> , 2004, 23, 1594-1598.	5.9	36
62	Frontline: Characterization of BT3 molecules belonging to the B7 family expressed on immune cells. <i>European Journal of Immunology</i> , 2004, 34, 2089-2099.	2.9	90
63	A co-evolution perspective of the TNFSF and TNFRSF families in the immune system. <i>Trends in Immunology</i> , 2003, 24, 387-394.	6.8	111
64	Potential of Tumor Necrosis Factor-Induced NF- $\kappa$ B Activation by Deacetylase Inhibitors Is Associated with a Delayed Cytoplasmic Reappearance of I $\kappa$ B $\alpha$ . <i>Molecular and Cellular Biology</i> , 2003, 23, 6200-6209.	2.3	89
65	<i>Coxiella burnetii</i> Avoids Macrophage Phagocytosis by Interfering with Spatial Distribution of Complement Receptor 3. <i>Journal of Immunology</i> , 2003, 170, 4217-4225.	0.8	49
66	Cutting Edge: Recruitment of the Ancestral <i>fyn</i> Gene During Emergence of the Adaptive Immune System. <i>Journal of Immunology</i> , 2002, 168, 2595-2598.	0.8	13
67	Mechanisms Regulating Expression of the Tumor Necrosis Factor-related light Gene. <i>Journal of Biological Chemistry</i> , 2002, 277, 42841-42851.	3.4	20
68	Synergistic Activation of Human Immunodeficiency Virus Type 1 Promoter Activity by NF- $\kappa$ B and Inhibitors of Deacetylases: Potential Perspectives for the Development of Therapeutic Strategies. <i>Journal of Virology</i> , 2002, 76, 11091-11103.	3.4	121
69	The distinct capacity of Fyn and Lck to phosphorylate Sam68 in T cells is essentially governed by SH3/SH2-catalytic domain linker interactions. <i>Oncogene</i> , 2002, 21, 7205-7213.	5.9	8
70	Role of ICAM-3 in the initial interaction of T lymphocytes and APCs. <i>Nature Immunology</i> , 2002, 3, 159-168.	14.5	142
71	Interaction with Simian Hck Tyrosine Kinase Reveals Convergent Evolution of the Nef Protein from Simian and Human Immunodeficiency Viruses Despite Differential Molecular Surface Usage. <i>Virology</i> , 2002, 295, 320-327.	2.4	5
72	The Tyrosine Kinase Hck Is an Inhibitor of HIV-1 Replication Counteracted by the Viral Vif Protein. <i>Journal of Biological Chemistry</i> , 2001, 276, 16885-16893.	3.4	55

#	ARTICLE	IF	CITATIONS
73	Parameters involved in the recognition of fresh human leukemic blasts by tumor-specific cytolytic T cell clones: a model study. <i>Leukemia Research</i> , 2000, 24, 823-830.	0.8	5
74	HIV-2 and SIV Nef Proteins Target Different Src Family SH3 Domains than Does HIV-1 Nef because of a Triple Amino Acid Substitution. <i>Journal of Biological Chemistry</i> , 2000, 275, 4171-4176.	3.4	37
75	Role of Tec kinase in nuclear factor of activated T cells signaling. <i>International Immunology</i> , 2000, 12, 1547-1552.	4.0	28
76	Tec Kinases. <i>Immunity</i> , 2000, 12, 373-382.	14.8	153
77	<sup>1</sup> H- <sup>13</sup> C nuclear magnetic resonance assignment and structural characterization of HIV-1 Tat protein. <i>Comptes Rendus De L'Académie Des Sciences Série 3, Sciences De La Vie</i> , 2000, 323, 883-894.	0.8	63
78	Human Immunodeficiency Virus Type 1 Nef Protein Sensitizes CD4+ T Lymphoid Cells to Apoptosis via Functional Upregulation of the CD95/CD95 Ligand Pathway. <i>Blood</i> , 1999, 93, 1000-1010.	1.4	101
79	Full Peptide Synthesis, Purification, and Characterization of Six Tat Variants. <i>Journal of Biological Chemistry</i> , 1999, 274, 11473-11478.	3.4	57
80	The Primate Lentivirus-Encoded Nef Protein Can Regulate Several Steps of the Viral Replication Cycle. <i>Virology</i> , 1999, 265, 173-177.	2.4	13
81	Simian Immunodeficiency Virus and Human Immunodeficiency Virus Type 1 Nef Proteins Show Distinct Patterns and Mechanisms of Src Kinase Activation. <i>Journal of Virology</i> , 1999, 73, 6152-6158.	3.4	41
82	Human Immunodeficiency Virus Type 1 Nef Protein Sensitizes CD4+ T Lymphoid Cells to Apoptosis via Functional Upregulation of the CD95/CD95 Ligand Pathway. <i>Blood</i> , 1999, 93, 1000-1010.	1.4	45
83	The Human Immunodeficiency Virus Type 1 NEF Protein Binds the Src-Related Tyrosine Kinase Lck SH2 Domain Through a Novel Phosphotyrosine Independent Mechanism. <i>Virology</i> , 1998, 247, 200-211.	2.4	42
84	Distinct Regulation of T-Cell Death by CD28 Depending on Both Its Aggregation and T-Cell Receptor Triggering: A Role for Fas-FasL. <i>Blood</i> , 1998, 92, 1350-1363.	1.4	10
85	Towards a consensus for a role of Nef in both viral replication and immunomodulation?. <i>Research in Virology</i> , 1997, 148, 23-30.	0.7	8
86	The role of HIV1 Nef in T-cell activation: Nef impairs induction of Th1 cytokines and interacts with the Src family tyrosine kinase Lck. <i>Research in Virology</i> , 1997, 148, 52-58.	0.7	13
87	Non-receptor protein tyrosine kinases as immune targets of viruses. <i>Trends in Immunology</i> , 1997, 18, 393-400.	7.5	27
88	CD28 can promote T cell survival through a phosphatidylinositol 3-kinase-independent mechanism. <i>European Journal of Immunology</i> , 1997, 27, 3283-3289.	2.9	39
89	Physical and Functional Interaction of Nef with Lck. <i>Journal of Biological Chemistry</i> , 1996, 271, 6333-6341.	3.4	165
90	Similarity between Nef of primate lentiviruses and p15E of murine and feline leukaemia viruses. <i>Aids</i> , 1996, 10, 441.	2.2	3

#	ARTICLE	IF	CITATIONS
91	Evidence for intact CD28 signaling in T cell hyporesponsiveness induced by the HIV-1nef gene. European Journal of Immunology, 1996, 26, 1788-1793.	2.9	21
92	The role of p21ras in CD28 signal transduction: triggering of CD28 with antibodies, but not the ligand B7-1, activates p21ras.. Journal of Experimental Medicine, 1994, 180, 1067-1076.	8.5	159
93	IDH1 Mutation Enhances Catabolic Flexibility and Mitochondrial Dependencies to Favor Drug Resistance in Acute Myeloid Leukemia. SSRN Electronic Journal, 0, , .	0.4	0